GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Quality Rank

New Ray Medicine International Holding (HKSE:06108) Quality Rank


View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

New Ray Medicine International Holding Quality Rank Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


New Ray Medicine International Holding (HKSE:06108) Business Description

Traded in Other Exchanges
N/A
Address
19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Executives
Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping 2201 Interest of corporation controlled by you
Qian Shenglei 2101 Beneficial owner
Zhang Jiang 2201 Interest of corporation controlled by you
Yang Fang 2202 Interest of your spouse
Zhou Ling 2101 Beneficial owner